ProCE Banner Activity

Cases in CLL Slides: High-Risk Patient Requiring First-line Therapy

Slideset Download
Download this slideset for expert perspectives on first-line treatment considerations for a patient with CLL with a del(17p) alteration.

Released: September 28, 2020

Expiration: September 27, 2021

No longer available for credit.

Share

Faculty

Matthew S. Davids

Matthew S. Davids, MD, MMSc

Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

Provided by the USF Health
ProCE Banner

Supporters

AbbVie Inc.

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Pharmacyclics an AbbVie Company

Partners

CLL Society

ProCE Banner

Faculty Disclosure

Primary Author

Matthew S. Davids, MD, MMSc

Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts